pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca clinical programs — 249 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
AstraZeneca projects
249 ClinicalTrials.gov programs sponsored by AstraZeneca.
AstraZeneca has 249 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
D6186C00001
AstraZeneca AB
Advanced Non-Small Cell Lung Cancer
1 trial -
D6187C00001
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D6405C00002
AstraZeneca AB
Chronic Kidney Disease and Albuminuria
1 trial -
D6830C00003
AstraZeneca AB
Asthma in adults who remain uncontrolled despite medium to high dose ICS plus LABA, and who are at risk of exacerbations.
1 trial -
D6972C00006
AstraZeneca AB
Chronic kidney disease (CKD) and hypertension.
1 trial -
D702KC00001
AstraZeneca AB
metastatic non-small cell lung cancer (NSCLC)
1 trial -
D7080C00001
AstraZeneca AB
Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma
1 trial -
D7230C00001
AstraZeneca AB
Multiple Myeloma
1 trial -
D7260C00001
AstraZeneca AB
Participants living with Obesity or Overweight with at least 1 comorbidity
1 trial -
D7261C00001
AstraZeneca AB
Type 2 Diabetes Mellitus
1 trial -
D7405C00001 (SYRUS)
AstraZeneca AB
B-Cell Acute Lymphoblastic Leukaemia
1 trial -
D7407C00001
AstraZeneca AB
Mantle Cell Lymphoma, Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
1 trial -
D7552C00001
AstraZeneca AB
Moderate-to-Severe Uncontrolled Asthma
1 trial -
D7830C00004
AstraZeneca AB
Non-cirrhotic non-alcoholic steatohepatitis with fibrosis
1 trial -
D7860C00006
AstraZeneca AB
Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
D7986C00001
AstraZeneca AB
Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
1 trial -
D798KC00001
AstraZeneca AB
Solid Tumors, SQ, NSQ NSCLC
1 trial -
D798MC00002
AstraZeneca AB
Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).
1 trial -
D8210C00003
AstraZeneca AB
Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
1 trial -
D8210C00005
AstraZeneca AB
Asthma
1 trial -
D8220C00036
AstraZeneca AB
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
1 trial -
D822GC00001
AstraZeneca AB
Treatment Naïve Mantle Cell Lymphoma
1 trial -
D8410C00001
AstraZeneca AB
Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, Module 4: advanced,unresectable and HER2+ metastatic solid tumours; NSCLC, HER2 activating mutation, Module 5: advanced,unresectable or metastatic solid tumours in breast, endometrial, ovarian and prostate cancer, Module 3: advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, IDH-mutant recurrent glioma, breast cancer (without BM), Module 2: IDH-mutant glioma
1 trial -
D8460C00004
AstraZeneca AB
Investigating obesity or overweight condition correlated to many co-morbidities
1 trial -
D8530C00002
AstraZeneca AB
Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer
1 trial -
D9077C00001
AstraZeneca AB
Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
1 trial -
D9090C00008
AstraZeneca AB
Chronic Heart Failure
1 trial -
D9102C00001
AstraZeneca AB
Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions
1 trial -
D9106C00002
AstraZeneca AB
Non-small Cell Lung Cancer (NSCLC)
1 trial -
D9181C00002
AstraZeneca AB
Asthma
1 trial -
D933LC00001
AstraZeneca AB
First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.
1 trial -
D9520C00001
AstraZeneca AB
Metastatic Prostate Cancer
1 trial -
D9571C00001
AstraZeneca AB
Relapsed/Refractory Classical Hodgkin Lymphoma
1 trial -
D967LC00001
AstraZeneca AB
Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer
1 trial -
D9690C00006
AstraZeneca AB
Crohn’s Disease and an Ileostomy
1 trial -
D9720C00001
AstraZeneca AB
Advanced Solid Tumors
1 trial -
D9720C00003
AstraZeneca AB
Metastatic Prostate Cancer
1 trial -
D9804C00001
AstraZeneca AB
Locally Advanced Resectable Gastroesophageal Adenocarcinoma
1 trial -
DESTINY-Breast07
AstraZeneca AB
HER2-positive Metastatic Breast Cancer
1 trial -
DS-8201a
AstraZeneca AB
Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology
1 trial -
DS-8201a
AstraZeneca AB
HER2 Expressing Tumors
1 trial -
Datopotamab deruxtecan
AstraZeneca AB
Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Patients With Muscle-Invasive Bladder Cancer
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIBIV)
1 trial -
OlympiaN
AstraZeneca AB
BRCA Mutations and Early Stage HER2-Negative Breast Cancer
1 trial -
PURSUIT
AstraZeneca AB
Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterol, which is a major risk factor for Cardiovascular Disease (CVD), such as Ischemic Heart Disease and Ischemic Stroke. CVD is a leading cause of global mortality and a contributor to disability.
1 trial -
Placebo for AZD4144, AZD4144
AstraZeneca AB
Sepsis-associated acute kidney injury (AKI)
1 trial -
Placebo for AZD5148, AZD5148
AstraZeneca AB
Recurrence of Clostridioides difficile Infection
1 trial
Frequently asked questions
How many clinical projects does AstraZeneca have?
249 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.